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Abstract
Background: The biological relevance of nuclear ErbB-2/HER2 (NuclErbB-2) presence in breast tumors remains
unexplored. In this study we assessed the clinical significance of ErbB-2 nuclear localization in primary invasive
breast cancer. The reporting recommendations for tumor marker prognostic studies (REMARK) guidelines were
used as reference.
Methods: Tissue microarrays from a cohort of 273 primary invasive breast carcinomas from women living in Chile,
a Latin American country, were examined for membrane (MembErbB-2) and NuclErbB-2 expression by an
immunofluorescence (IF) protocol we developed. ErbB-2 expression was also evaluated by immunohistochemistry
(IHC) with a series of antibodies. Correlation between NuclErbB-2 and MembErbB-2, and between NuclErbB-2 and
clinicopathological characteristics of tumors was studied. The prognostic value of NuclErbB-2 in overall survival (OS)
was evaluated using Kaplan-Meier method, and Cox model was used to explore NuclErbB-2 as independent
prognostic factor for OS.
Results: The IF protocol we developed showed significantly higher sensitivity for detection of NuclErbB-2 than IHC
procedures, while its specificity and sensitivity to detect MembErbB-2 were comparable to those of IHC procedures.
We found 33.6% NuclErbB-2 positivity, 14.2% MembErbB-2 overexpression by IF, and 13.0% MembErbB-2 prevalence
by IHC in our cohort. We identified NuclErbB-2 positivity as a significant independent predictor of worse OS in
patients with MembErbB-2 overexpression. NuclErbB-2 was also a biomarker of lower OS in tumors that
overexpress MembErbB-2 and lack steroid hormone receptors.
Conclusions: We revealed a novel role for NuclErbB-2 as an independent prognostic factor of poor clinical
outcome in MembErbB-2-positive breast tumors. Our work indicates that patients presenting NuclErbB-2 may need
new therapeutic strategies involving specific blockage of ErbB-2 nuclear migration.
Background
Human epidermal growth factor receptor 2 (ErbB-2/
HER2), one of the members of the ErbB family of mem-
brane receptor tyrosine kinases, is a major player in the
breast cancer scenario [1]. Membrane ErbB-2 (Mem-
bErbB-2) overexpression is associated with poor clinical
outcome [2]. At present, the recombinant humanized
anti-ErbB-2 monoclonal antibody trastuzumab is suc-
cessfully used for treatment of MembErbB-2-positive
breast cancer in the metastatic and the adjuvant settings
[3,4]. However, a significant percentage of tumors dis-
play primary or acquired trastuzumab resistance [5].
Notably, the dogma of ErbB-2 action as a membrane
tyrosine kinase which induces the activation of mito-
genic signaling pathways to promote breast cancer
growth [1], has been challenged by the demonstration
that MembErbB-2 migrates to the nuclear compartment,
where it acts as a transcription factor (TF) [6]. Up to
date, cyclooxygenase-2 (COX-2) gene is the only one
whose expression has been shown to be modulated
through the role of ErbB-2 as a TF in mammary tumor
cells [6]. Correlation between ErbB-2 nuclear presence
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already been reported [6,7].
On the other hand, our recent findings have for the
first time demonstrated that ErbB-2 acts also as a tran-
scriptional coactivator [8]. We found that in the nucleus
of breast cancer cells, ErbB-2 assembles a transcriptional
complex in which it functions as a coactivator of the
signal transducer and activator of transcription 3 (Stat3)
to promote the expression of cyclin D1 [8], another
gene known to induce breast cancer proliferation [9,10].
An exciting and novel finding of our study was the
demonstration of the direct involvement of Nuclear
ErbB-2 (NuclErbB-2) in breast cancer growth [8]. These
findings led us to build our hypothesis that NuclErbB-2
presence could be associated with highly proliferative
breast cancer subtypes which show a poor clinical out-
come. Our present results have for the first time
demonstrated that NuclErbB-2 is indeed a powerful and
independent prognostic factor of poor clinical outcome
in MembErbB-2-positive breast tumors.
Methods
Patients and Tissue Microarays (TMAs)
Paraffin-embedded tissue samples from 346 consecu-
tively archived invasive breast carcinomas were selected
for construction of TMA blocks from the files of the
Histopathology Department of Temuco Hospital, Chile,
from 1998 to 2006. From 273 patients, follow-up data
was available for up to 13 years with a median follow-
up time of 53 months. All patients were treated with
surgery. This study was conducted with the approval of
the Institutional Review Board on Human Research of
Universidad de La Frontera (UF), and informed written
consents were obtained from all patients before inclu-
sion. The Board reviewed and approved the collection of
tumor specimens, our survey data, and all clinical and
pathological information as well as the restrospective
biomarker analysis on anonymized specimens from the
Temuco Hospital archival cohort. Pre-treatment patient
staging was classified according to the American Joint
Committee on Cancer (AJCC) system [11] through the
Elston and Ellis histological grading system [12]. TMAs
were constructed at the UF TMA Core Facility. In brief,
H&E sections of all tumors were re-evaluated by a
pathologist (PG) for suitability for TMA construction.
Representative areas of tumor sections for each case
were selected and circled to match the blocks for the
tissue microarray. Blocks matching the circled slides
were then retrieved to prepare the recipient block for
the microarray. To assure the representation of selected
cores, two areas of tumor sections per case were deter-
mined for assembly of the recipient blocks. Each target
area on the selected blocks was punched to form a 2-
mm-diameter tissue core, and placed consecutively on
~3 × 2 cm recipient blocks using a tissue microarrayer
(Beecher Instrument, Silver S p r i n g ,M D ) .T i s s u em i c r o -
arrays were then cut to 5 μm sections and placed on
silane-coated glass slides, and the first and last slide
were stained for H&E.
Fluorescence in situ hybridization (FISH)
FISH was done according to PathVysion™ (Vysis, Inc,
Downers Grove, IL) guidelines. ErbB-2 gene/chromo-
some 17 centromere signals ratio more than 2.2 was
considered ErbB-2 amplification.
Immunohistochemistry
Antigen retrieval was performed in 10 mM sodium
citrate buffer pH 6 for 20 min at 96-98°C. Slides were
incubated with primary antibodies as follows: c-erb-B2
clone A0485 (dilution 1:300 overnight at 4°C; Dako Car-
pinteria, CA), ErbB-2 clone C-18 (dilution 1:100, 1 h
room temperature; Santa Cruz Biotechnology Inc., Santa
Cruz, CA), RBT-HER2 (dilution 1:250, 1 h room tem-
perature; Bio SB, Santa Barbara, CA), SP3 (dilution
1:100 overnight at 4°C; NeoMarkers, Fremont, CA). Sec-
tions were subsequently incubated with polydetector
HRP system (Bio SB) and developed in 3-3’-diaminoben-
zidine tetrahydrochloride. Immunostainings were run
with known positive and negative tumor controls and
were blindly evaluated by two pathologists (PG and JCR)
who ignored the results of FISH. ErbB-2 was scored
according to the American Society of Clinical Oncology/
College of American Pathologists (ASCO/CAP) guide-
lines [13]. Scores 2+ in which FISH confirmed ErbB-2
amplification, and 3+ were considered positive for Mem-
bErbB-2 overexpression. Estrogen (ER) and progesterone
receptor (PR) were evaluated by IHC with clone 6F11
(Novocastra Laboratories, U.K) and clone hPRa2+hPRa3
(NeoMarkers, Freemont, CA), respectively and scored as
described [14].
Immunofluorescence
Antigen retrieval was performed by immersing the sec-
tions in 10 mM sodium citrate buffer pH 6 and micro-
waving at high power for 4 min. Slides were blocked in
Modified Hank’s Buffer (MHB) with 5% bovine serum
albumin for 30 min and were incubated overnight at 4°
C with the following ErbB-2 primary antibodies: C-18,
raised against the ErbB-2 carboxy (C)-terminal region
[8], 9G6, directed against the ErbB-2 amino (N) termi-
nus, (1:50, Santa Cruz), e2-4001 raised against the ErbB-
2 carboxy (C)-terminal region (1:50, Thermo Scientific,
Pittsburgh, PA) and with phospho ErbB-2 (Tyr 877) and
phospho ErbB-2 (Tyr 1221/1222) antibodies (1:50, Cell
Signaling, Beverly, MA). Slides were then incubated with
the corresponding Alexa 488-conjugated antibody
(1:1000, Molecular Probes, Eugene, OR). Reduction of
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bation with Sudan Black B 0.1% (Sigma-Aldrich, St.
Louis, MO). Nuclei were stained with propidium iodide
or DAPI (4’,6-diamidino-2-phenylindole). Slides were
analyzed by a Nikon Eclipse E800 confocal laser micro-
scopy system. Negative controls were carried out with
MHB instead of primary antibodies and using an ErbB-2
competitive peptide (Santa Cruz). NuclErbB-2-positive
and -negative C4HD tumors from the model of mam-
mary tumors induced by progestins were also used as
controls [8]. Slides were independently scored by PG
and JCR. Score discrepancies were re-evaluated and
reconciled on a two-headed microscope. A third pathol-
ogist (EM) participated in IF staining and evaluation.
MembErbB-2 and NuclErbB-2 expressions were evalu-
ated in duplicate arrays.
Statistics
Analyses were performed using STATA version 11 soft-
ware (Stata Corp., College Station, TX).  tests were
applied to study concordance between MembErbB-2
levels determined with the different antibodies. Correla-
tions between categorical variables were performed
using the c
2-test or Fisher’s exact test when the number
of observations obtained for analysis was small. Specifi-
cally, Fisher’s exact test was selected when the number
of expected values was under five, because it uses the
exact hypergeometric distribution to compute the p-
value [15]. The c
2-test is basically an approximation of
the results from the exact test, so few observations
could potentially render erroneous results. Cumulative
overall survival probabilities were calculated according
to the Kaplan-Meier method, and statistical significance
was analyzed by log-rank test. Multivariate analysis was
performed using the Cox multiple hazards model.
Adjustment for significant confounders was done to
avoid increased bias and variability, unreliable confi-
dence interval coverage, and problems with the model
associated to the small size of our sample [16]. Variables
included in the Cox model were those which resulted
statistically significant (p < 0.05) in the log rank test
(nuclear ErbB-2 staining, N, age and tumor grade). The
remaining variables were excluded from our analysis
(ER, PR, tumor size, clinical stage). All the tests of sta-
tistical significance were two-sided. P values < 0.05 were
regarded as statistically significant. Guidelines for
reporting tumor markers (REMARK) [17] were used, as
outlined in Additional file 1.
Results
ErbB-2 nuclear localization in human breast cancers
Since there are no previous reports on the clinical sig-
nificance of NuclErbB-2 in breast cancer, we decided to
tackle this issue first by conducting a retrospective study
in a cohort of 273 primary invasive breast carcinomas
from women living in Chile, a Latin American country.
All these patients were treated with primary surgery.
Our purpose was to assess the value of NuclErbB-2 as a
prognostic marker within the context of the commonly
used risk factors and the molecular subtype classifica-
tion. The clinical and pathological characteristics of
these specimens are shown in Table 1. TMAs from 226
Table 1 Patient clinicopathological characteristics
Characteristic N° patients %
Total number of patients 273
Age (years)
Mean 55.5
SD 13.7
Menopausal status
Premenopausal 111 41
Postmenopausal 162 56
Tumor size
T1 58 21
T2 148 54
T3 45 17
T4 22 8
Lymph node status
N0 118 43
N1 83 30
N2 72 27
Distant metastasis
M0 256 94
M1 17 6
Metastatic sites location
Bone 7
Liver 3
Skin 2
Brain 2
Not documented 3
Clinical stage
I3 9 1 4
II 137 50
III 81 30
IV 16 6
Tumor grade
14 5 1 7
2 134 50
38 6 3 3
Not documented 8
Hormone receptor status, crossed results
ER+PR+
a 140 52
ER+PR- 50 18
ER-PR+ 4 2
ER-PR- 75 28
Not documented 4
aER: estrogen receptor; PR: progesterone receptor
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MembErbB-2 expression by IHC using the rabbit mono-
clonal antibody RBT-HER2 and the rabbit polyclonal
antibody A0485, which was approved by the Food and
Drug Administration (FDA) and is routinely used for
ErbB-2 evaluation [18]. We have recently detected
MembErbB-2 and NuclErbB-2 in breast cancer cells by
IF using the ErbB-2 rabbit polyclonal antibody C-18 [8].
Here we also assessed the ability of C-18 to detect
ErbB-2 by IHC. MembErbB-2 levels were scored as pre-
viously described [13]. Scores of 3+ and only those of 2
+ in which FISH confirmed ErbB-2 amplification were
considered positive for MembErbB-2. Concordance
between IHC scores of 2+ and FISH results were 92.1%
( = 0.62) for RBT-HER2, 90.9% ( = 0.61) for A0458,
and 91.2% ( = 0.61) for C-18. Our findings showed
that 12.9% of the tumors showed MembErbB-2 overex-
pression with RBT-HER2, 13.8% with A0458, and 12.4%
with C-18 (Table 2). Substantial concordance was found
between 2+ and 3+ results obtained with RBT-HER2
and A0485 (91.9%,  = 0.63), RBT-HER2 and C-18
(91.7%,  = 0.64), and A0485 and C-18 (92.2%,  =
0.64). Representative tumor samples stained with all
three antibodies are shown in Figure 1A-C.
We next explored the nuclear presence of ErbB-2 by
IHC. We did not find NuclErbB-2 in our tumors using
RBT-HER2 (Figure 1A). Contrastingly, IHC with A0485
showed nuclear staining in some samples (Figure 1B), in
accordance with seminal findings [6]. We also observed
NuclErbB-2 in the tumors using C-18 (Figure 1C). To
determine whether the difference in sensitivity to detect
NuclErbB-2 between RBT-HER2 and the other two anti-
bodies, A0485 and C-18, was due to an exclusive feature
o fR B T - H E R 2 ,w ea l s os t a i n e dt h eT M A su s i n gS P 3 ,
another rabbit monoclonal antibody [18]. We found no
nuclear staining in the tumor samples using SP3 (data
not shown), suggesting that rabbit monoclonal antibo-
dies may be less sensitive to detect NuclErbB-2 by IHC
than rabbit polyclonal antibodies. Since we have most
recently found that C-18 is exquisitely sensitive for the
detection of MembErbB-2 and NuclErbB-2 in breast
cancer cells by IF [8,19], we decided to assess ErbB-2
levels and cellular localization by IF in our TMAs. For
this purpose, we first evaluated a series of commercially
available total and phospho-ErbB-2 antibodies for their
capacity to detect protein expression and activation by
IF in paraffin-embedded tumor sections. As summarized
in Table 3, we found that only C-18 was effective in
detecting ErbB-2 protein expression. Levels of Mem-
bErbB-2 detected by IF were semiquantified using the
same scores as those used in the IHC staining. On the
other hand, an immunoreactivity score for NuclErbB-2
has not yet been established. Thus, we here scored
NuclErbB-2 levels detected by IF considering both the
percentage of ErbB-2 positive cells and staining inten-
sity. A score of 0 represents faint or no staining in less
than 10% of cells, 1+ weak nuclear staining in 10-25%, 2
+ moderate staining in 26-50%, and 3+ strong staining
in > 50% of cells (Figure 1D). Scores of 2+ and 3+ were
considered positive for NuclErbB-2 presence. To assure
the specificity of our results, C4HD tumors from the
model of mammary carcinogenesis induced by proges-
tins [20] were included in the TMAs. We recently
showed a strong NuclErbB-2 localization in these
tumors [8] that was completely abrogated by the trans-
fection of a mutant ErbB-2 (hErbB-2ΔNLS) [21] unable
to translocate to the nuclear compartment and which
acts as a dominant negative inhibitor of endogenous
ErbB-2 nuclear migration [8]. C4HD tumors were used
as positive controls and C4HD tumors transfected with
the hErbB-2ΔNLS as negative controls. Representative
tumor samples are shown in Figure 1E. NuclErbB-2
positivity detected by IF in our cohort was 33.6% and
no correlation was found between MembErbB-2 and
NuclErbB-2 presence (Table 4). This is in contrast to
previous findings using A0485 antibody in IHC or IF,
which showed a direct correlation between MembErbB-
2 and NuclErbB-2 positivity in breast tumors [6,7]. In
order to assess whether this discrepancy might be due
to differences in how NuclErbB-2 positivity was defined
in those studies and in ours, we re-evaluated the corre-
lation between MembErbB-2 and NuclErbB-2 using less
stringent criteria for NuclErbB-2 positivity. We included
tumors with 1+ score within the NuclErbB-2-positive
group, but again found no significant correlation
between MembErbB-2 overexpression and its nuclear
presence (Table 4). We then added to our original
cohort 73 patients. No correlation between MembErbB-
2 and NuclErbB-2 presence was found in this larger
cohort (Table 4). Having established a score for
NuclErbB-2 positivity, we went back to our IHC staining
of the arrays to semiquantify NuclErbB-2 levels. We
found 4% NuclErbB-2 presence by IHC using A0485
and a significant correlation between MembErbB-2 and
NuclErbB-2-positivity (P < 0.0001). On the other hand,
Table 2 Correlation between MembErbB-2 prevalence
detected by immunohistochemistry
Antibody MembErbB-2, n(%) Total N (%)
Negative Positive
RBT-HER2 175 (87.1) 26 (12.9) 201
A0485 181(86.2) 29 (13.8) 210
C-18 177 (87.6) 25 (12.4) 202
Because of the absence of some core sections on the slides, 201 patient
samples could be analyzed for MembErbB-2 with RBT-HER2, 210 with A0485,
and 202 with C-18. Scores of 3+ and only those of 2+ in which FISH
confirmed ErbB-2 amplification were considered positive for MembErbB-2
overexpression
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Page 4 of 13Figure 1 Cellular localization of ErbB-2 in tumor samples. A. IHC staining using RBT-HER2. Representative tumors with 2+ and 3+ scores
of membrane ErbB-2 expression (400×). Inset shows FISH of ErbB-2 gene amplification in the tumor scored 2+ (1000×). B.I H Co fE r b B - 2
(400×) using A0485. Representative tumors showing only membrane ErbB-2 or membrane and nuclear ErbB-2 staining C.I H Co fE r b B - 2
(400×) using C-18. Examples of tumors showing exclusively membrane, membrane and nuclear or only nuclear positivity. D and E. IF staining
of ErbB-2 with C-18. D. Nuclear ErbB-2 score. Nuclei were stained with propidium iodide (red). E. Examples of tumors showing only
membrane, membrane and nuclear, and exclusive nuclear ErbB-2 expression (+2 and +3 scores). Nuclei were stained with DAPI (blue). In A
to C and in E orange arrows indicate membrane ErbB-2 positivity and in B, C,a n dE white arrows indicate nuclear ErbB-2 presence.
Membrane ErbB-2 levels in both IHC and IF were scored according to the American Society of Clinical Oncology/College of American
Pathologists (ASCO/CAP) guidelines for ErbB-2/HER2 testing [13]. A score 0 represents no staining, 1+ weak, incomplete membrane staining
in any proportion of tumor cells, 2+ complete membrane staining that is either non uniform or weak but with obvious circumferential
distribution in at least 10% of tumor cells, or invasive tumors showing intense, complete membrane staining in 30% or fewer tumor cells, 3+
strong complete membrane staining in > 30% of tumor cells.
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12%, and we found no correlation between MembErbB-
2 and NuclErbB-2 positivity (P = 0.07). Representative
IHC staining pattern for ErbB-2 with C-18 is shown in
Figure 1C. These findings demonstrate that indeed
A0485 has lower sensitivity than C-18 for the detection
of NuclErbB-2. Substantial to excellent overall concor-
dance was found between MembErbB-2 positivity
detected by IF and IHC with the different antibodies
(Table 5). MembErbB-2 positivity showed an inverse
relationship with the status of the steroid hormone
receptors (HR) estrogen (ER) and progesterone (PR), as
previously described [22] (Table 6).
Association of NuclErbB-2 with risk factors and clinical
outcome in breast cancer subtypes
We evaluated the relationship between NuclErbB-2 (2+
and 3+ scores) and the clinicopathological characteris-
tics in 273 patients of our cohort. NuclErbB-2 was sig-
nificantly associated with tumor size, lymph node
positivity, and clinical stage (Table 7). As widely
acknowledged in breast tumors [2], patients from our
cohort bearing tumors with MembErbB-2 overexpres-
sion showed a significant worse overall survival (OS)
than those lacking it (Figure 2A). Kaplan-Meier survival
analysis showed no significant differences in OS between
patients whose tumors expressed NuclErbB-2 and those
with tumors lacking NuclErbB-2 (Figure 2B). We then
explored the prognostic value of NuclErbB-2 in the
group of patients that displayed MembErbB-2 overex-
pression. We found a significant association between
NuclErbB-2 and the presence of distant metastasis at
diagnosis (Table 7). In addition, patients bearing tumors
with both MembErbB-2 and NuclErbB-2 had worse OS
compared with patients whose tumors showed only
MembErbB-2 (Figure 2C). In the molecular classification
of breast cancer, tumors which lack ER and PR and
overexpress MembErbB-2 (MembErbB-2+/ER-PR-)
(Table 7) have been included in the ErbB-2-positive
molecular subtype, associated with poor outcome
[23-25]. Here we observed a significantly lower OS in
the subset of patients with MembErbB-2+/ER-PR-
tumors expressing NuclErbB-2 as compared to those
whose tumors lack NuclErbB-2 (Figure 2D). Breast
Table 3 Comparison of ErbB-2 antibodies capacity to recognize ErbB-2 protein by immunofluorescence in paraffin-
embedded tumor sections
Source Isotype Clone Terminus
a MembErbB-2 NuclErbB-2
ErbB-2 antibodies
Santa cruz Biotechnology rabbit polyclonal C-18 carboxy Yes Yes
mouse monoclonal 9G 6 amino No No
Thermo
Scientific
mouse
Monoclonal
e2-4001 carboxy No No
Phospho ErbB-2 antibodies
phosphotyrosine 877 Cell Sinaling rabbit polyclonal carboxy No No
phosphotyrosine 1221/1222 Cell Signaling rabbit polyclonal 6B12 carboxy No No
a Localization of the epitope against which each ErbB-2 antibody was raised
Table 4 Correlation between NuclErbB-2 and MembErbB-2 expression studied by immunofluorescence with C-18
antibody
MembErbB-2, n (%) Total N (%) P value
Negative Positive
NuclErbB-2 expression in the 226 patient cohort
Negative (0/1+) 126 (55.7)
a 24 (10.6) 150 (66.4) 0.265
b
Positive (2+/3+) 68 (30.0) 8 (3.7) 76 (33.6)
Total N (%) 194 (85.8) 32 (14.2) 226 (100)
Negative (0) 87 (38.5) 19 (8.4) 106 (46.9) 0.127
Positive (1+/2+/3+) 107 (47.4) 13 (5.7) 120 (53.1)
Total N (%) 194 (85.8) 32 (14.2) 226 (100)
NuclErbB-2 expression in the 298 patient cohort
c
Negative (0/1+) 171 (57.5) 30 (10.0) 201 (67.4) 0.176
Positive (2+/3+) 88 (29.5) 9 (3.0) 97 (32.6)
Total N (%) 259 (86.9) 39 (13.1) 298 (100)
a Percentage of the total cohort.
b Correlation between NuclErbB-2 and MembErbB-2 expression was determined by c2 test.
c We added to our original cohort 73
patients whose NuclErbB-2 and MembErbB-2 status by immunofluorescence staining we knew, but had not been included in our complete study because we
lacked information regarding several clinicopathologic characteristics
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(MembErbB-2-/ER+PR+), included in the luminal A
molecular subtype [23-25], represent the subgroup with
better prognosis of this study cohort. We found that the
presence of NuclErbB-2 within this subgroup is signifi-
cantly associated with larger tumor size, lymph node
positivity, and higher clinical stages and grades (Table
7). However, we did not find significant differences in
OS between patients whose tumors exhibited NuclErbB-
2 and those lacking it (Figure 2E). Our cohort has a
very small number (21) of patients with tumors Mem-
bErbB-2+/ER+PR+, a molecular signature of the recently
defined as luminal-ErbB-2-positive subgroup [26].
Although a trend was observed for NuclErbB-2 presence
and reduced survival in this subgroup (Figure 2F), the
difference was not statistically significant (P =0 . 2 8 8 )
because owing to limited sample size, the test was not
powerful enough.
Finally, multivariate analysis was performed using the
Cox multiple hazards model. Adjustment for significant
confounders was done to avoid increased bias and varia-
bility, unreliable confidence interval coverage, and pro-
blems with the model associated to the small size of our
sample [16]. Variables included in the Cox model were
those which resulted statistically significant (p < 0.05) in
the log rank test (nuclear ErbB-2 staining, N, age and
tumor grade). The remaining variables were excluded
from our analysis (ER, PR, tumor size, clinical stage).
Our findings demonstrated that NuclErbB-2 positivity
was a significant independent predictor of worse survival
in patients with MembErbB-2 (HR: 3.153, 95% CI:
1.118-8.891, P = 0.030). On the contrary, NuclErbB-2
presence did not have significant independent prognos-
tic value in the overall patient population (HR:0.598,
95% CI:0.310-1.155, P = 0.126).
Discussion
We here identify a novel role of NuclErbB-2 as a bio-
marker of poor clinical outcome in MembErbB-2-posi-
tive breast tumors.
First, we developed an IF protocol using the rabbit
polyclonal antibody C-18, raised against the ErbB-2 car-
boxy (C)-terminal region [8], for the detection of ErbB-2
in paraffin-embedded tumor sections. We chose C-18
because we had already revealed its exquisite sensitivity
to detect NuclErbB-2 and MembErbB-2 in breast cancer
cells by IF [8,19]. Since seminal findings [6] and our
own previous work [8] demonstrated that full-length
Table 5 Concordance between detection of MembErbB-2 expression by immunofluorescence and
immunohistochemistry
MembErbB-2 (IF
a C-18), n (%) Total N (%) Overall
concordance (%)

statistics
d
Negative Positive
MembErbB-2 (IHC
b RBT HER2)
Negative 168 (83.4)
c 7 (3.5) 175 (87.1) 96 0.84
Positive 1 (0.4) 25 (12.7) 26 (12.9)
MembErbB-2 (IHC A0485)
Negative 170 (80.9) 11 (5.2) 181 (86.2) 90 0.6
Positive 10 (4.8) 19 (9.1) 29 (13.8)
MembErbB-2 (IHC C-18)
Negative 168 (83.2) 9 (4.5) 177 (87.6) 93 0.7
Positive 5 (2.5) 20 (9.9) 25 (12.4)
a IF: Immunofluorescence.
b IHC: Immunohistochemistry.
c Percentage of the total cohort.
d  statistics (with a value of 1.0 indicating perfect agreement and a
value of -1.0 indicating perfect disagreement) revealed excellent to substantial levels of concordance between detection of MembErbB-2 positivityb yI Fw i t hC -
18 and by IHC with RBT-HER2, A0485, and C-18 antibodies
Table 6 Correlation between estrogen and progesterone receptor status and MembErbB-2 expression
MembErbB-2 (IF)
a, n (%) Total N (%) P value MembErbB-2 (IHC)b, n (%) Total N (%) P value
Negative Positive Negative Positive
ER
c expression
Negative 54 (23.90)
d 20 (8.8) 74 (32.7) 0.001
e 54 (26.8) 16 (8.0) 70 (34.8) 0.002
Positive 140 (61.9) 12 (5.3) 152 (67.3) 121 (60.2) 10 (5.0) 131 (65.2)
PR
f expression
Negative 90 (39.8) 24 (10.6) 114 (50.4) 0.003 88 (43.8) 20 (10.0) 108 (53.7) 0.011
Positive 104 (46.0) 8 (3.5) 112 (49.6) 87 (43.2) 6 (3.0) 93 (46.2)
a IF: Immunofluorescence staining performed with C-18 antibody.
b IHC: Immunohistochemistry staining performed with RBT-HER2 antibody.
c ER: Estrogen
receptor.
d Percentage of the total cohort.
e Correlation between variables was determined by c2 analysis.
f PR: Progesterone receptor
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Page 7 of 13Table 7 Association between NuclErbB-2 expression and clinicopathological characteristics in breast cancer
Total cohort
(N = 273)
MembErbB-2+
N=4 0
MembErbB-2+/ER-PR-
(N = 21)
MembErbB-2-/ER+PR+
(N = 145)
NuclErbB-2, n (%) P
value
NuclErbB-2, n (%) P
value
NuclErbB-2, n (%) P
value
NuclErbB-2, n (%) P
value
Negative Positive Negative Positive Negative Positive Negative Positive
Tumor size
≤ 20 mm 46 (26.3) 13
(13.3)
0.012
a 4 (14.8) 2 (16.7) 0.885
b 2 (14.3) 1 (14.3) 1
b 25 (31.6) 9 (13.8) 0.012
a
> 20 mm 129
(73.7)
85
(86.7)
23 (85.2) 10
(83.3)
12 (85.7) 6 (85.7) 54 (68.4) 56
(86.2)
Total N (%) 175
(64.0)
98
(36.0)
27 (69.2) 12
(30.8)
14 (66.7) 7 (33.3) 79 (54.9) 65
(45.1)
Nodal metastasis
Negative 82 (46.9) 33
(33.7)
0.034
a 10 (35.7) 4 (33.3) 0.885
b 7 (50.0) 2 (28.6) 0.642
b 45 (57.0) 24
(36.4)
0.013
a
Positive 93 (53.1) 65
(66.3)
18 (64.3) 8 (66.7) 7 (50.0) 5 (71.4) 34 (43.0) 42
(63.6)
Total N (%) 175
(64.0)
98
(36.0)
28 (70.0) 12
(30.0)
14 (66.7) 7 (33.3) 79 (54.5) 66
(45.5)
Distant metastasis
M0 167
(95.4)
89
(90.8)
0.130
a 27 (96.4) 9 (75.0) 0.049
b 14 (100) 7 (100) 75 (94.9) 62
(93.9)
1
b
M1 8 (4.6) 9 (9.2) 1 (3.6) 3 (25.5) - - 4 (5.1) 4 (6.1)
Total N (%) 175
(64.0)
98
(36.0)
28 (70.0) 12
(30.0)
14 (66.7) 7 (33.3) 79 (54.5) 66
(45.5)
Clinical stage
I 31 (17.7) 8 (8.2) 0.031
a 4 (14.3) 2 (20.0) 0.847
b 2 (14.3) 1 (14.3) 1
b 18 (22.8) 4 (6.1) 0.005
b
II+III+IV 144
(82.3)
90
(91.8)
24 (85.7) 8 (80.0) 12 (85.7) 6 (85.7) 61 (77.2) 62
(93.9)
Total N (%) 175
(64.0)
98
(36.0)
28 (73.7) 10
(26.3)
14 (66.7) 7 (33.3) 79 (54.5) 66
(45.5)
Tumor grade
Well to moderately
differentiated
c
121
(70.3)
57
(61.3)
0.134
a 16 (59.2) 5 (45.5) 0.438
a 9 (64.3) 3 (42.9) 0.397
b 65 (83.3) 42
(68.9)
0.044
a
Poorly differentiated 51 (29.7) 36
(38.7)
11 (40.8) 6 (54.5) 5 (35.7) 4 (57.1) 13 (16.7) 19
(31.1)
Total N (%) 172
(65.0)
93
(35.0)
27 (71.0) 11
(29.0)
14 (66.7) 7 (33.3) 78 (56.1) 61
(43.9)
ER
d expression
Negative 53 (30.6) 26
(26.8)
0.540
a 14 (51.9) 8 (72.7) 0.296
b 14 (100) 7 (100) 1 (1.3) 2 (3.0) 0.457
b
Positive 120
(69.4)
71
(73.2)
13 (48.1) 3 (27.3) - - 78 (98.7) 64
(97.0)
Total N 173
(64.0)
97
(36.0)
27 (71.0) 11
(29.0)
14 (66.7) 7 (33.3) 79 (54.5) 66
(45.5)
PR
e expression
Negative 82 (47.4) 43
(44.8)
0.681
a 18 (67.7) 9 (81.8) 0.452
b 14 (100) 7 (100) 15 (19.0) 14
(21.2)
0.739
a
Positive 91 (52.6) 54
(55.2)
9 (33.3) 2 (18.2) - - 64 (81.0) 52
(78.8)
Total N 173
(64.0)
97
(36.0)
27 (71.0) 11
(29.0)
14 (66.7) 7(33.3) 79 (54.5) 66
(45.5)
a c2 Test.
b Fisher’s exact test
c Well to moderately differentiated: tumor grade 1 + 2, poorly differentiated: tumor grade 3.
d ER: estrogen receptor
e PR: progesterone receptor
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Page 8 of 13ErbB-2 is present in the nuclear compartment of breast
cancer cells, we also tested the mouse monoclonal 9G6
antibody directed against the ErbB-2 amino (N)
terminus, which we previously found recognized
NuclErbB-2 and MembErbB-2 by IF in breast cancer
cells [8]. In addition, we used another ErbB-2
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Figure 2 Kaplan-Meier survival analysis and log-rank test were performed to correlate the levels of NuclErbB-2 with overall patient
survival in the different breast cancer subtypes. Kaplan-Meier analysis showing the correlation of MembErbB-2 overexpression with overall
survival in our total cohort is shown in A.
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Page 9 of 13monoclonal antibody directed against the ErbB-2 C-ter-
minus (clone e2-4001) as well as two polyclonal antibo-
dies that recognize ErbB-2 phosphorylated at tyrosine
1222 or 877, two sites we have already revealed are
phosphorylated in NuclErbB-2 [8]. We found that none
of these antibodies detected NuclErbB-2 or MembErbB-
2 by IF staining of the tissue arrays. This failure could
be explained by the fact that we could not appropriately
retrieve the single site or epitope on the antigen recog-
nized by the monoclonal antibodies, or the site specifi-
cally containing the phosphorylated residue in the case
of the two anti-phospho ErbB-2 polyclonal antibodies,
due to the harsh conditions used in the preparation of
the tissue blocks. On the contrary, given that polyclonal
antibodies, such as C-18, recognize a broad range of epi-
topes on the antigen, including denaturation-resistant
epitopes, we successfully detected ErbB-2 by IF in the
tissue arrays with C-18.
Our present findings using the IF protocol with the C-
18 antibody showed 33.6% NuclErbB-2 positivity and
14.2% MembErbB-2 overexpression in our Chilean
cohort. This percentage of NuclErbB-2 staining is com-
parable to the one (38%) reported in breast tumors for
nuclear expression of the epidermal growth factor recep-
tor (EGF-R), another member of the ErbBs family [27].
Excellent to substantial levels of concordance were
found between MembErbB-2 overexpression determined
by IF with the C-18 antibody and by IHC using C-18,
BT-HER2 or A0485 antibodies, indicating that the IF
protocol we developed is as sensitive and specific as
routinely used IHC staining procedures, including those
using the Food and Drug Administration (FDA)-
approved A0485 antibody, the same clone used in the
commercial HercepTest immunostaining kit, also
approved by the FDA. We found no correlation between
NuclErbB-2 and MembErbB-2 positivity, in contrast to
two previous works which reported a direct correlation
between MembErbB-2 and NuclErbB-2 presence in
breast tumors [6,7]. In said works, ErbB-2 localization
was studied by either IHC [6] or IF [7] using the A0485
antibody. This discrepancy is unlikely due to differences
in how NuclErbB-2 positivity was defined in those stu-
dies and in ours since we found the same results after
we re-evaluated the correlation applying a less stringent
criterion for NuclErbB-2 positivity. No correlation was
found either when we extended the cohort under study.
Another difference between said study exploring
NuclErbB-2 prevalence in breast cancer by IF with
A0485 [7] and ours, is the lower incidence of NuclErbB-
2 detected by A0485 (12.3%) as compared to the one we
found with C-18. A probable explanation for these dis-
parities is that C-18 has much greater sensitivity for
detecting NuclErbB-2 than A0485. Therefore, a signifi-
cant number of samples which scored negative for
NuclErbB-2 IF staining with A0485 are in fact detected
by C-18, accounting for both the higher NuclErbB-2
positivity and the lack of correlation between Mem-
bErbB-2 and NuclErbB-2 presence. Several of our data
support this hypothesis. First, our results of NuclErbB-2
incidence studied by IHC using A0485 and C-18
demonstrated that A0485 showed a significantly lower
percentage of NuclErbB-2 presence (4%) as compared to
C-18 (12%). Second, in accordance with the previous
work mentioned above [6], we found a good correlation
between MembErbB-2 overexpression and NuclErbB-2-
positivity in the IHC staining with A0485, but no corre-
lation between NuclErbB-2 and MembErbB-2 positivity
in the IHC staining with C-18. Our recent findings
demonstrating that in the nucleus of breast cancer cells
ErbB-2 is associated with Stat3 and PR [8], could help
to explain the different sensitivity of both antibodies. A
larger number of epitopes recognized by A0485 could
be blocked by NuclErbB-2 association with other pro-
teins e.g. Stat3 and PR, than those recognized by C-18.
On the other hand, the prevalence of NuclErbB-2 was
lower when we used C-18 in IHC than when we used it
in IF. This is likely due to the fact that while in the IHC
staining with C-18 we used the standard conditions for
membrane ErbB-2 detection [13], we introduced modifi-
cations in our IF protocol to enhance the sensitivity of
NuclErbB-2 detection, including optimization of the
antigen retrieval protocol and improvement of the con-
ditions of interaction between antibodies and antigens,
as described in a pioneering work assessing the clinical
value of EGF-R nuclear presence [27]. The fact that the
discrepancy in C-18 sensitivity when used in IF or in
IHC is observed for the detection of NuclErbB-2 but
not for MembErbB-2 argues for the possibility that dif-
ferences in the conformation of MembErbB-2 and
NuclErbB-2 and/or the association of NuclErbB-2 with
other proteins may restrict antibody access to
NuclErbB-2.
Although there are no extensive studies assessing the
frequency of MembErbB-2 positivity in LA women in
their own native countries [28], a series of startling
works have shown the role of MembErbB-2 overexpres-
sion as predictor of poor outcome in breast cancer
cohorts from Brasil [29,30]. Here we found 13% of
MembErbB-2 overexpression by IHC and 14.2% by IF in
our LA cohort. MembErbB-2-positive rates among Cau-
casian and Asian women, in whom most studies have
been done to date, currently tend to be below 20%, with
reports by most investigators stating that the real posi-
tive rate ranges between 15%-20% [31]. Therefore, our
present findings for the first time show that the inci-
dence of MembErbB-2 positivity in LA women living in
their own countries is not significantly different from
that of women living in developed countries.
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Page 10 of 13MembErbB-2 overexpression has long been found to
be associated with poor clinical outcome [2,31,32]. We
here demonstrate that patients whose tumors expressed
MembErbB-2 and NuclErbB-2 have worse OS compared
with those with tumors showing only MembErbB-2.
Moreover, NuclErbB-2 positivity was a significant inde-
pendent predictor of poor survival in patients with
MembErbB-2 overexpression. NuclErbB-2 also resulted
a marker of lower overall survival in the subgroup of
patients with tumors MembErbB-2+/ER-PR-, included
in the ErbB-2-positive molecular subtype [23-25]. This
latter finding for the first time highlights NuclErbB-2
presence as a molecular signature that might help to
define two biologically distinct subsets of tumors within
the ErbB-2-positive molecular subtype. The role of
NuclErbB-2 as a TF [6], as well as our recent discoveries
showing that ErbB-2 acts also as a coactivator [8] may
underlie the poor outcome of tumors with NuclErbB-2.
T h ec o m b i n e dc a p a c i t yo fE r b B - 2t oa c t i v a t em i t o g e n i c
signaling pathways when located in the membrane and
to act straight in the nucleus as a transcriptional regula-
tor might drive the assembly of a gene network different
from the one assembled in tumors with exclusive Mem-
bErbB-2 presence. This network would be involved in
growth, metastasis and/or response to anti-ErbB-2
therapies, such as trastuzumab. Blockage of MembErbB-
2 capacity to activate cytoplasmic signaling cascades is
one of the mechanisms of trastuzumab action [5,33,34].
Therefore, a likely explanation to trastuzumab resistance
could be ErbB-2 nuclear presence and function as a
transcriptional regulator. Strong support to this possibi-
lity is provided by our findings that abrogation of ErbB-
2 nuclear localization inhibits in vitro and in vivo
growth of breast tumors expressing both NuclErbB-2
and MembErbB-2 [8].
The significant number of early stage tumors with no
lymph node metastasis we have in our total cohort may
account for the lack of NuclErbB-2 prognosis value in
our overall population. Indeed although MembErbB-2
positivity is a poor prognostic factor in axillary node
positive and negative tumors, the clinical significance of
MembErbB-2 in early stage cancer is not yet completely
understood [32,35-38]. On the other hand, our recent
findings on PR and ErbB-2 interaction [8] provide a
most exciting explanation for the comparable OS in
MembErbB-2-/ER+PR+tumors with and without
NuclErbB-2. We revealed that in HR+breast tumors, PR
co-opts ErbB-2 function not only as membrane tyrosine
kinase but also as transcriptional regulator [8]. In such
scenario, endocrine therapies targeting ER, which in
turn modulate the effects of PR, an ER-target gene,
would also abolish ErbB-2 action at both membrane and
nucleus.
Several key features of our cohort, such as levels of
MembErbB-2 overexpression, the inverse correlation
between HR presence and MembErbB-2 overexpression,
and the fact that most of the tumors were in early
stages, are comparable to those of the North American
population [2,22,39] supporting extrapolation of our
conclusions onto North American women. We hope our
present findings will encourage further studies of
NuclErbB-2 role as biomarker in larger populations stra-
tified according to their treatment with endocrine ther-
apy or chemotherapy and, in the case of MembErbB-2
overexpressing tumors, with trastuzumab or more
recently with lapatinib.
Conclusions
Our novel findings highlight the importance of develop-
ing new therapies to block ErbB-2 nuclear presence,
such as our recent use of a mutant ErbB-2 that
abolishes endogenous ErbB-2 nuclear migration [8].
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